Inova's program is the only fully-integrated pulmonary hypertension program in the region and builds on the national reputation of Inova's Advanced Lung Disease and Transplant Programs. Under the directorship of Oksana A. Shlobin, MD, FCCP, a care team comprised of numerous medical and support experts meets weekly to review and establish treatment plans for individual patients. Our team members present at pulmonary conferences throughout the world including ISHLT, ATS, Chest, ERS, PHA annual meetings and regional programs.
Dr. Shlobin serves on the Accreditation and Pre-Review Accreditation committees for PHA. She is also the workforce leader for the PH Council for the Standards and Guidelines Committee of the ISHLT and served for two years as the PH Group liaison to the Program Committee for ISHLT. Lastly, Dr. Shlobin was recently elected to be a member of the Pulmonary Vascular Disease Network Oversight Committee for the ACCP.
Dr. Nathan had the honor of participating in the most recent World Symposium on Pulmonary Hypertension in Nice, France in 2018, where he served as the task force co-chair for the Group 3 PH committee.
Dr. King has recently been selected to serve as a member of the Guidelines Oversight Committee for the ACCP. Dr. King also serves as the chair of the data safety monitoring board for a NIH-sponsored study on pulmonary hypertension.